Systemic sclerosis prevalence and comorbidities in the US, 2001–2002

References

• Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367: 1683–91
   Google Scholar
• Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003;29:239–54
   PubMed Web of Science ®Google Scholar
• Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819–26
   Google Scholar
• Williams JP, Meyers JA. Immune-mediated inflammatory disorders (I.M.I.D.s): the economic and clinical costs. Am J Manag Care 2002;8(21 Suppl):S664–81; quiz S82–5
   Google Scholar
• Clements PJ, Becvar R, Drosos AA, et al. Assessment of gastrointestinal involvement. Clin Exp Rheumatol 2003;21(3 Suppl 29):S15–18
   Google Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2:119–25
   PubMed Web of Science ®Google Scholar
• Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340–50
   PubMed Web of Science ®Google Scholar
• McGlynn E. Exploring Policy Issues in Managed Care: Six Illustrative Case Studies. RAND Corporation, 2001
   Google Scholar
• Schlesinger M, Druss B, Thomas T. No exit? The effect of health status on dissatisfaction and disenrollment from health plans. Health Serv Res 1999;34:547–76
   Google Scholar
• Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005;52:2415–24
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Silverstein MD, Silver RM. Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol 2001;28:2031–7
   Google Scholar
• Robinson D, Jr., Hackett M, Wong J, Kimball AB, Cohen R, Bala M. Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002. Curr Med Res Opin 2006;22: 989–1000
   Google Scholar
• Wallace DJ, Hahn BH, eds. Dubois’ Lupus Erythematosus, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2002
   Google Scholar
• Sloka S. Observations on recent studies showing increased co-occurrence of autoimmune diseases. J Autoimmun 2002; 18:251–7
   PubMed Web of Science ®Google Scholar
• Rector TS, Wickstrom SL, Shah M, et al. Specificity and sensitivity of claims-based algorithms for identifying members of Medicare+Choice health plans that have chronic medical conditions. Health Serv Res 2004;39(6 Pt 1):1839–57
   Google Scholar
• Woodward M. Epidemiology: Study Design and Data Analysis, 1st edn. Boca Raton: Chapman & Hall, 1999
   Google Scholar
• Zhang J, Yu KF. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690–1
   PubMed Web of Science ®Google Scholar
• Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care 2003;41:84–99
   PubMed Web of Science ®Google Scholar
• Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8–27
   PubMed Web of Science ®Google Scholar
• Southern DA, Quan H, Ghali WA. Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care 2004;42:355–60
   Google Scholar
• Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006;33:1113–16
   PubMed Web of Science ®Google Scholar
• Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003;62:728–31
   PubMed Web of Science ®Google Scholar
• Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis. J Rheumatol 2002;29:1867–73
   PubMed Web of Science ®Google Scholar
• Chung L, Krishnan E, Chakravarty EF. Hospitalizations and mortality in systemic sclerosis: results from the Nationwide Inpatient Sample. Rheumatology (Oxford) 2007;46:1808–13
   Google Scholar
• Fleischmann RM. Is there a need for new therapies for rheumatoid arthritis? J Rheumatol Suppl 2005;73:3–7; discussion 29–30
   Google Scholar
• Nietert PJ, Silver RM, Mitchell HC, et al. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol 2005;32:1888–92
   PubMed Web of Science ®Google Scholar
• Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005;118:2–10
   PubMed Web of Science ®Google Scholar
• Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99–104
   PubMed Web of Science ®Google Scholar
• Goff DC, Jr., Pandey DK, Chan FA, et al. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 2000;160:197–202
   PubMed Web of Science ®Google Scholar
• Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf 2001;10:389–92
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum 2005;34:714–20
   PubMed Web of Science ®Google Scholar
• Allcock RJ, Forrest I, Corris PA, et al. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 2004;43:596–602
   PubMed Web of Science ®Google Scholar
• Le Guern V, Mahr A, Mouthon L, et al. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology (Oxford) 2004;43:1129–37
   PubMed Web of Science ®Google Scholar
• Feghali-Bostwick C, Medsger TA, Jr., Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum 2003;48:1956–63
   Google Scholar
• Furst DE, Khanna D, Mattucci-Cerinic M, et al. Scleroderma -developing measures of response. J Rheumatol 2005;32:2477–80
   Google Scholar
• Garabrant DH, Lacey JV, Jr., Laing TJ, et al. Scleroderma and solvent exposure among women. Am J Epidemiol 2003;157:493–500
   Google Scholar
• Khanna D, Furst DE, Clements PJ, et al. Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol 2005;32:832–40
   PubMed Web of Science ®Google Scholar
• Maitre A, Hours M, Bonneterre V, et al. Systemic sclerosis and occupational risk factors: role of solvents and cleaning products. J Rheumatol 2004;31:2395–401
   PubMed Web of Science ®Google Scholar
• Nordenbaek C, Johansen JS, Halberg P, et al. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Scand J Rheumatol 2005;34:293–7
   PubMed Web of Science ®Google Scholar
• Magnant J, de Monte M, Guilmot JL, et al. Relationship between occupational risk factors and severity markers of systemic sclerosis. J Rheumatol 2005;32:1713–8
   PubMed Web of Science ®Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35–42
   PubMed Web of Science ®Google Scholar
• Sultan N, Pope JE, Clements PJ. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma. Rheumatology (Oxford) 2004;43:472–8
   Google Scholar